Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

15. März 2017 08:00 ET | Quelle: Zogenix, Inc.

Zogenix to Participate in the Oppenheimer 27th Annual Healthcare Conference

EMERYVILLE, Calif., March 15, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
09. März 2017 16:01 ET | Quelle: Zogenix, Inc.

Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results

Top-Line Data for First Phase 3 Study Expected in 3Q 2017 ZX008 Phase 3 Pivotal Study 1504 Initiated – Target Data Readout by End of 2017 Planned Initiation of Phase 3 study of ZX008 in Lennox...
02. März 2017 08:00 ET | Quelle: Zogenix, Inc.

Zogenix to Release Fourth Quarter and Full-Year 2016 Financial Results and Host Conference Call and Webcast on March 9

EMERYVILLE, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
01. März 2017 08:00 ET | Quelle: Zogenix, Inc.

Zogenix Receives Orphan Drug Designation in the European Union for ZX008 in Lennox Gastaut Syndrome

EMERYVILLE, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
15. Februar 2017 08:00 ET | Quelle: Zogenix, Inc.

Zogenix to Participate in the 2017 RBC Capital Markets Healthcare Conference

EMERYVILLE, Calif., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
13. Februar 2017 08:00 ET | Quelle: Zogenix, Inc.

Zogenix Announces Initiation of Clinical Efficacy Portion of Study 1504 for ZX008 in Dravet Syndrome

Study 1504 Part of Phase 3 Program for ZX008 in Dravet Syndrome Safety and Efficacy Portion of Study Expanded from EU to Include Sites in U.S. and Canada EMERYVILLE, Calif., Feb. 13, 2017 (GLOBE...
08. Februar 2017 08:00 ET | Quelle: Zogenix, Inc.

Zogenix to Participate in the Leerink Partners 6th Annual Global Healthcare Conference

EMERYVILLE, Calif., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
30. Januar 2017 08:00 ET | Quelle: Zogenix, Inc.

Zogenix Announces Issuance of U.S. Patent for ZX008 in Dravet Syndrome

EMERYVILLE, Calif., Jan. 30, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
05. Januar 2017 16:01 ET | Quelle: Zogenix, Inc.

Zogenix Announces CFO Transition

EMERYVILLE, Calif., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
05. Dezember 2016 08:00 ET | Quelle: Zogenix, Inc.

Zogenix Announces New Efficacy and Safety Data for ZX008 in Treatment of Seizures in Lennox Gastaut Syndrome & Dravet Syndrome

New Clinical Data Presented at 70th Annual American Epilepsy Society MeetingPosters Highlighting Potential Protective Effect of ZX008 in Pre-Clinical Model of Sudden Unexpected Death in Epilepsy...

Vorherige Seite

Nächste Seite